LNTH Overview

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. The Company's product categories include Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Others. The Company's Radiopharmaceutical Oncology products help healthcare professionals (HCPs) find, fight and follow cancer. The Company's Precision Diagnostic products assist HCPs to find and follow diseases. Its Strategic Partnerships include biomarkers and digital solutions in support of its partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of its assets geographically. The Company's commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.

Wall Street analysts forecast LNTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LNTH is82.17 USD with a low forecast of 70.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Lantheus Holdings Inc revenue for the last quarter amounts to 384.00M USD, increased 1.39 % YoY.

Lantheus Holdings Inc. EPS for the last quarter amounts to 0.41 USD, decreased -77.09 % YoY.

Lantheus Holdings Inc (LNTH) has 808 emplpoyees as of January 30 2026.

Today LNTH has the market capitalization of 4.00B USD.